NuCana plc (NCNA) stock
Close on Nov 12, 2026Market cap $3.87MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- £2.89M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -257.95%
Fundamentals
- EPS, diluted
- 0.00 GBP
- Free cash flow
- -£7.47M
- Diluted shares
- 20.93B
Trading
- Previous close
- $0.94
- Open
- $0.94
- Day's range
- $0.88 – $0.94
- Volume
- 31,899
- Average volume (20 days)
- 26,700
- Beta (5 years)
- 1.48
- RSI (14 days)
- 37.9
- Volatility (1 year)
- 75.3%
- Relative volume
- 0.42×
- WACC
- 12.3%
Market cap history
Month-end market cap since 2017, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | NCNA | S&P 500 | Difference | NCNA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -13.9% | -2.7% | −11.2 pts | ||
| 3 months | -35.0% | -1.7% | −33.2 pts | ||
| Year to date | -74.2% | +11.9% | −86.1 pts | ||
| 1 year | -75.5% | +12.0% | −87.4 pts | ||
| 3 years | -100.0% | +78.2% | −178.1 pts | -92.3% | +21.2% |
| 5 years | -100.0% | +73.2% | −173.2 pts | -85.5% | +11.6% |
Twelve years at a glance
Fiscal years 2014 to 2025, GBP
Operating income
EPS, diluted
Free cash flow
Press releases
Releases NuCana filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About NuCana
Pharmaceutical Preparations
NuCana plc is a clinical-stage biopharmaceutical company focused on developing therapies for oncology patients. The company utilizes its proprietary ProTide technology to create nucleoside analogs aimed at overcoming cancer drug resistance and enhancing therapeutic efficacy. Its development pipeline includes clinical candidates such as NUC-7738, NUC-3373, and Acelarin, which are evaluated for the treatment of solid tumors and other cancer indications. The company designs its therapeutic candidates to serve cancer patients worldwide.
Company profile, executives and historyNuCana stock: common questions
What is NuCana's stock price?
NCNA closed at $0.93 on Nov 12, 2026, down 1.04% on the day.
What is NuCana's market cap?
NuCana was worth $3.87M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is NCNA's P/E ratio?
NuCana lost money over fiscal 2025 (diluted EPS 0.00 GBP), so it has no meaningful P/E ratio.
Does NuCana pay a dividend?
No. NuCana has not paid a cash dividend over the last twelve months.
How has NCNA stock performed over the past year?
Including dividends, NCNA returned -75.5% over the past year, against +12.0% for the S&P 500.
Who are NuCana's competitors?
Companies most similar to NuCana by business, industry and size include PRLD, APLM, BDRX, PYXS, NBP.
See a number that looks wrong?